Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 984

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 9B
Chunk 984
---
During the Company’s fourth quarter, no director or officer adopted or terminated a
Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.

64

PART III

Item 10. Directors, Executive Officers and
Corporate Governance

The information
required by this Item 10 will be included under the captions “Directors and Executive Officers”, “Information as to
Nominees and Other Directors”, “Information Regarding Meetings and Committees of the Board”, “Compliance with
Section 16(a) of the Exchange Act”, “Code of Ethics”, “Corporate Governance” and as otherwise set forth
in the Company’s Definitive Proxy Statement and is incorporated herein by reference or, alternatively will be included, by amendment
to this Form 10-K under cover of Form 10-K/A no later than 120-days after the end of our fiscal year covered by this report.

Item 11. Executive Compensation

The information
required by this Item 11 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by
reference.

Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters

The
information required by this Item 12 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated
herein by reference.

Item 13. Certain Relationships and Related
Transactions and Director Independence

The
information required by this Item 13 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated
herein by reference.

Item 14. Principal Accounting Fees and Services

The information required by this Item
14 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.

65

PART IV

Item 15. Exhibits and Financial Statement Schedules

Exhibit No.
 
Description
 
Incorporated by Reference

2.1
 
Agreement and Plan of Merger, dated February 26, 2025, by and among Renovaro, Inc., Renovaro Acquisition Sub and Biosymetrics, Inc.
 
Incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on February 28, 2025. 

2.2 
 
Second Amendment to Stock Purchase Agreement, dated February 13, 202